Chronic hepatitis B virus (HBV) infection is the most common cause of hepatic fibrosis and hepatocellular carcinoma (HCC),mainly as a result of chronic necroinflammatory liver disease. A characteristic feature of chro...Chronic hepatitis B virus (HBV) infection is the most common cause of hepatic fibrosis and hepatocellular carcinoma (HCC),mainly as a result of chronic necroinflammatory liver disease. A characteristic feature of chronic hepatitis B infection,alcoholic liver disease and nonalcoholic fatty liver disease (NAFLD) is hepatic steatosis. Hepatic steatosis leads to an increase in lipid peroxidation in hepatocytes,which,in turn,activates hepatic stellate cells (HSCs). HSCs are the primary target cells for inflammatory and oxidative stimuli,and these cells produce extracellular matrix components. Chronic hepatitis B appears to progress more rapidly in males than in females,and NAFLD,cirrhosis and HCC are predominately diseases that tend to occur in men and postmenopausal women. Premenopausal women have lower hepatic iron stores and a decreased production of proinflammatory cytokines. Hepatic steatosis has been observed in aromatase-deficient mice,and has been shown to decrease in animals after estradiol treatment. Estradiol is a potent endogenous antioxidant which suppresses hepatic fibrosis in animal models,and attenuates induction of redox sensitive transcription factors,hepatocyte apoptosis and HSC activation by inhibiting a generation of reactive oxygen species in primary cultures. Variant estrogen receptors are expressed to a greater extent in male patients with chronic liver disease than in females. These lines of evidence suggest that the greater progression of hepatic fibrosis and HCC in men and postmenopausal women may be due,at least in part,to lower production of estradiol and a reduced response to the action of estradiol. A better understanding of the basic mechanisms underlying the sex-associated differences in hepatic fibrogenesis and carciogenesis may open up new avenues for the prevention and treatment of chronic liver disease.展开更多
目的综合评价激素补充治疗对更年期综合征患者生理、心理的生存质量的影响。方法观察性研究125例更年期综合征患者,按有无经过激素治疗分为2组:A组65例患者未经任何激素类药物治疗,B组60例经过了6个月的激素补充治疗;测量基本参数,并填...目的综合评价激素补充治疗对更年期综合征患者生理、心理的生存质量的影响。方法观察性研究125例更年期综合征患者,按有无经过激素治疗分为2组:A组65例患者未经任何激素类药物治疗,B组60例经过了6个月的激素补充治疗;测量基本参数,并填写改良Kupperman评分、焦虑自评量表(self-rating anxiety scale,SAS)、抑郁自评量表(self-rating depression scale,SDS)、绝经期生存质量量表(menopause-specific quality of life questionnaire,MENQOL)。结果 60例实施激素补充治疗的更年期女性的Kupperman指数,SAS、SDS、MENQOL的结果均显著低于未经治疗者;35例患者治疗前后4项量表评分差异也有统计学意义。结论激素补充治疗不仅可以显著缓解患者围绝经期出现的躯体不适,还能够改善焦虑、抑郁程度,提高更年期综合征患者的生存质量。展开更多
文摘Chronic hepatitis B virus (HBV) infection is the most common cause of hepatic fibrosis and hepatocellular carcinoma (HCC),mainly as a result of chronic necroinflammatory liver disease. A characteristic feature of chronic hepatitis B infection,alcoholic liver disease and nonalcoholic fatty liver disease (NAFLD) is hepatic steatosis. Hepatic steatosis leads to an increase in lipid peroxidation in hepatocytes,which,in turn,activates hepatic stellate cells (HSCs). HSCs are the primary target cells for inflammatory and oxidative stimuli,and these cells produce extracellular matrix components. Chronic hepatitis B appears to progress more rapidly in males than in females,and NAFLD,cirrhosis and HCC are predominately diseases that tend to occur in men and postmenopausal women. Premenopausal women have lower hepatic iron stores and a decreased production of proinflammatory cytokines. Hepatic steatosis has been observed in aromatase-deficient mice,and has been shown to decrease in animals after estradiol treatment. Estradiol is a potent endogenous antioxidant which suppresses hepatic fibrosis in animal models,and attenuates induction of redox sensitive transcription factors,hepatocyte apoptosis and HSC activation by inhibiting a generation of reactive oxygen species in primary cultures. Variant estrogen receptors are expressed to a greater extent in male patients with chronic liver disease than in females. These lines of evidence suggest that the greater progression of hepatic fibrosis and HCC in men and postmenopausal women may be due,at least in part,to lower production of estradiol and a reduced response to the action of estradiol. A better understanding of the basic mechanisms underlying the sex-associated differences in hepatic fibrogenesis and carciogenesis may open up new avenues for the prevention and treatment of chronic liver disease.
文摘目的综合评价激素补充治疗对更年期综合征患者生理、心理的生存质量的影响。方法观察性研究125例更年期综合征患者,按有无经过激素治疗分为2组:A组65例患者未经任何激素类药物治疗,B组60例经过了6个月的激素补充治疗;测量基本参数,并填写改良Kupperman评分、焦虑自评量表(self-rating anxiety scale,SAS)、抑郁自评量表(self-rating depression scale,SDS)、绝经期生存质量量表(menopause-specific quality of life questionnaire,MENQOL)。结果 60例实施激素补充治疗的更年期女性的Kupperman指数,SAS、SDS、MENQOL的结果均显著低于未经治疗者;35例患者治疗前后4项量表评分差异也有统计学意义。结论激素补充治疗不仅可以显著缓解患者围绝经期出现的躯体不适,还能够改善焦虑、抑郁程度,提高更年期综合征患者的生存质量。
